Caphosol^®

Caphosol, a topical oral agent, is a U.S. patented, prescription medical device that lubricates the mucosa and helps maintain the integrity of the oral cavity through its mineralizing potential. The distinguishing feature of Caphosol is its high concentrations of calcium and phosphate ions. Caphosol is indicated in the U.S. as an adjunct to standard oral care in treating oral mucositis caused by radiation or high dose chemotherapy. Relief of dryness of the oral mucosa in these conditions is associated with an amelioration of pain.

Caphosol is also indicated for dryness of the mouth (hyposalivation) or throat (xerostomia) regardless of the cause or whether the conditions are temporary or permanent. Caphosol is an unclassified medical device and is marketed under a 510(k) Premarket Notification Application.

In EU, Caphosol is an electrolyte solution designed to moisten, lubricate and clean the oral cavity including the mucosa of the mouth, tongue and oropharynx. Caphosol is a Class I CE marked medical device indicated for dryness of the mouth and oropharynx (hyposalivation, xerostomia), regardless of the cause and regardless of whether the condition is temporary or permanent. Caphosol is also indicated as an adjunct to standard oral care in the prevention and treatment of the mucositis that may be caused by radiation or high dose chemotherapy. Relief of dryness of the oral mucosa in these conditions is associated with amelioration of pain.

For further information on Caphosol, in the USA please visit Caphosol.Com, in Europe and the Rest of the World Caphosol.EU

USA - Important Safety Information:
Avoid eating or drinking at least 15 minutes after use. Patients restricted to a low sodium diet should consult their physician before use. In the USA, federal law restricts this device to sale by or on the 0rder of a physician or dentist. Keep out of reach of children.

For information on our full range of products, where they are available and prescribing information, please see the Summary table.